Abstract PS5-07-23: Novel Targeting of the Microenvironment to Decrease Metastatic Recurrence of High-Risk TNBC: A Randomized Phase 2 Study of Tetrathiomolybdate (TM), an oral copper depletion agent plus capecitabine +/- pembrolizumab in patients with breast cancer at high risk of recurrence (NCT06134375)
Year: 2026
Type: conference-abstract
Source: Clinical Cancer Research
Institutions: Dartmouth–Hitchcock Medical Center, Dartmouth Cancer Center, NYU Langone’s Laura and Isaac Perlmutter Cancer Center, New York University, Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Indiana University Health, Indiana University Indianapolis, Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Emory University, Winship Cancer Institute, Massachusetts General Hospital, Memorial Sloan Kettering Cancer Center, Weill Cornell Medicine
Language: English
Subfield: Cancer Research
Domain: Life Sciences
Open Access status: closed
OpenAlex ID: W7129526269
Cites:
Cited by:
Related to: